These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35205705)

  • 1. Risk of Second Primary Thyroid Cancer in Women with Breast Cancer.
    Cieszyńska M; Kluźniak W; Wokołorczyk D; Cybulski C; Huzarski T; Gronwald J; Falco M; Dębniak T; Jakubowska A; Derkacz R; Marciniak W; Lener M; Woronko K; Mocarz D; Baszuk P; Bryśkiewicz M; Narod SA; Lubiński J
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population.
    Górski B
    Hered Cancer Clin Pract; 2006 Aug; 4(3):142-52. PubMed ID: 20223018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A risk of breast cancer in women - carriers of constitutional CHEK2 gene mutations, originating from the North - Central Poland.
    Bąk A; Janiszewska H; Junkiert-Czarnecka A; Heise M; Pilarska-Deltow M; Laskowski R; Pasińska M; Haus O
    Hered Cancer Clin Pract; 2014 Apr; 12(1):10. PubMed ID: 24713400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CHEK2 mutations and the risk of papillary thyroid cancer.
    Siołek M; Cybulski C; Gąsior-Perczak D; Kowalik A; Kozak-Klonowska B; Kowalska A; Chłopek M; Kluźniak W; Wokołorczyk D; Pałyga I; Walczyk A; Lizis-Kolus K; Sun P; Lubiński J; Narod SA; Góźdż S
    Int J Cancer; 2015 Aug; 137(3):548-52. PubMed ID: 25583358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome.
    Lener MR; Kashyap A; Kluźniak W; Cybulski C; Soluch A; Pietrzak S; Huzarski T; Gronwald J; Lubiński J
    Cancer Res Treat; 2017 Apr; 49(2):430-436. PubMed ID: 27488870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
    Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J
    J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of the
    Gąsior-Perczak D; Kowalik A; Gruszczyński K; Walczyk A; Siołek M; Pałyga I; Trepka S; Mikina E; Trybek T; Kopczyński J; Suligowska A; Ślusarczyk R; Gonet A; Jaskulski J; Orłowski P; Chrapek M; Góźdź S; Kowalska A
    Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33530461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.
    Cybulski C; Wokołorczyk D; Jakubowska A; Huzarski T; Byrski T; Gronwald J; Masojć B; Deebniak T; Górski B; Blecharz P; Narod SA; Lubiński J
    J Clin Oncol; 2011 Oct; 29(28):3747-52. PubMed ID: 21876083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland.
    Cybulski C; Wokołorczyk D; Huzarski T; Byrski T; Gronwald J; Górski B; Debniak T; Masojć B; Jakubowska A; van de Wetering T; Narod SA; Lubiński J
    Breast Cancer Res Treat; 2007 Mar; 102(1):119-22. PubMed ID: 16897426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer?
    Lener MR; Scott RJ; Kluźniak W; Baszuk P; Cybulski C; Wiechowska-Kozłowska A; Huzarski T; Byrski T; Kładny J; Pietrzak S; Soluch A; Jakubowska A; Lubiński J
    Int J Cancer; 2016 Aug; 139(3):601-6. PubMed ID: 27038244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An inherited NBN mutation is associated with poor prognosis prostate cancer.
    Cybulski C; Wokołorczyk D; Kluźniak W; Jakubowska A; Górski B; Gronwald J; Huzarski T; Kashyap A; Byrski T; Dębniak T; Gołąb A; Gliniewicz B; Sikorski A; Switała J; Borkowski T; Borkowski A; Antczak A; Wojnar L; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Sikorska-Radek P; Matych J; Wilkosz J; Różański W; Kiś J; Bar K; Bryniarski P; Paradysz A; Jersak K; Niemirowicz J; Słupski P; Jarzemski P; Skrzypczyk M; Dobruch J; Domagała P; Narod SA; Lubiński J;
    Br J Cancer; 2013 Feb; 108(2):461-8. PubMed ID: 23149842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel founder CHEK2 mutation is associated with increased prostate cancer risk.
    Cybulski C; Huzarski T; Górski B; Masojć B; Mierzejewski M; Debniak T; Gliniewicz B; Matyjasik J; Złowocka E; Kurzawski G; Sikorski A; Posmyk M; Szwiec M; Czajka R; Narod SA; Lubiński J
    Cancer Res; 2004 Apr; 64(8):2677-9. PubMed ID: 15087378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A personalised approach to prostate cancer screening based on genotyping of risk founder alleles.
    Cybulski C; Wokołorczyk D; Kluźniak W; Kashyap A; Gołąb A; Słojewski M; Sikorski A; Puszyński M; Soczawa M; Borkowski T; Borkowski A; Antczak A; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Domagała P; Piotrowski K; Menkiszak J; Krzystolik K; Gronwald J; Jakubowska A; Górski B; Dębniak T; Masojć B; Huzarski T; Muir KR; Lophatananon A; Lubiński J; Narod SA;
    Br J Cancer; 2013 Jun; 108(12):2601-9. PubMed ID: 23722471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHEK2 1100delC, IVS2+1G>A and I157T mutations are not present in colorectal cancer cases from Turkish population.
    Bayram S; Topaktaş M; Akkız H; Bekar A; Akgöllü E
    Cancer Epidemiol; 2012 Oct; 36(5):453-7. PubMed ID: 22521562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHEK2-positive breast cancers in young Polish women.
    Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Kowalska E; Oszurek O; Narod SA; Lubinski J
    Clin Cancer Res; 2006 Aug; 12(16):4832-5. PubMed ID: 16914568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer.
    Domagala P; Wokolorczyk D; Cybulski C; Huzarski T; Lubinski J; Domagala W
    Breast Cancer Res Treat; 2012 Apr; 132(3):937-45. PubMed ID: 21701879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients.
    Suspitsin EN; Sherina NY; Ponomariova DN; Sokolenko AP; Iyevleva AG; Gorodnova TV; Zaitseva OA; Yatsuk OS; Togo AV; Tkachenko NN; Shiyanov GA; Lobeiko OS; Krylova NY; Matsko DE; Maximov SY; Urmancheyeva AF; Porhanova NV; Imyanitov EN
    Hered Cancer Clin Pract; 2009 Feb; 7(1):5. PubMed ID: 19338682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival of bladder or renal cancer in patients with CHEK2 mutations.
    Złowocka-Perłowska E; Dębniak T; Słojewski M; van de Wetering T; Tołoczko-Grabarek A; Cybulski C; Scott RJ; Lubiński J
    PLoS One; 2021; 16(9):e0257132. PubMed ID: 34499690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk of gastric cancer in carriers of CHEK2 mutations.
    Teodorczyk U; Cybulski C; Wokołorczyk D; Jakubowska A; Starzyńska T; Lawniczak M; Domagała P; Ferenc K; Marlicz K; Banaszkiewicz Z; Wiśniowski R; Narod SA; Lubiński J
    Fam Cancer; 2013 Sep; 12(3):473-8. PubMed ID: 23296741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHEK2 mutations and HNPCC-related colorectal cancer.
    Suchy J; Cybulski C; Wokołorczyk D; Oszurek O; Górski B; Debniak T; Jakubowska A; Gronwald J; Huzarski T; Byrski T; Dziuba I; Gogacz M; Wiśniowski R; Wandzel P; Banaszkiewicz Z; Kurzawski G; Kładny J; Narod SA; Lubiński J
    Int J Cancer; 2010 Jun; 126(12):3005-9. PubMed ID: 19876921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.